)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
SpectraCure
SpectraCure (SPEC) investor relations material
SpectraCure Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary21 Aug, 2026
Executive summary
Advanced clinical studies for Q-PRO® system in recurrent and primary localized prostate cancer, with phase 2 of the recurrence study nearing completion and positive safety and efficacy data observed.
Strengthened recruitment base with leading clinics in Europe and North America, expanding to additional sites in Germany pending regulatory approval.
Completed a rights issue post-period, raising approximately 25.7 MSEK before costs, supporting continued clinical and regulatory activities.
Financial highlights
Q2 2026 net loss after tax: -6,828 TSEK (Q2 2025: -7,202 TSEK); H1 2026 net loss: -12,967 TSEK (H1 2025: -13,517 TSEK).
Earnings per share for Q2: -0.01 SEK (Q2 2025: -0.03 SEK); H1: -0.02 SEK (H1 2025: -0.06 SEK).
Operating cash flow for Q2: -4,815 TSEK (Q2 2025: 4,172 TSEK); H1: -9,593 TSEK (H1 2025: -1,475 TSEK).
Equity at June 30, 2026: 93,576 TSEK (June 30, 2025: 134,884 TSEK); cash and equivalents: 7,633 TSEK (9,250 TSEK).
Solid equity ratio of 83% (78% in prior year period).
Outlook and guidance
Focus remains on completing phase 2 of the recurrence study by spring, with preparations for phase 3 underway.
The recent capital raise is expected to fund operations into Q1 2027; further financing may be needed depending on clinical progress and option exercise.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SpectraCure
- Clinical progress and new funding strengthen outlook, but further financing is required.SPEC
Q1 2026 - Clinical advances and expanded trials marked 2025, but a major impairment drove a larger net loss.SPECQ4 2025
- Promising clinical results offset by a major write-down and ongoing funding needs.SPECQ3 2025
- Clinical progress and new funding strengthen position despite ongoing losses.SPECQ2 2025
- Losses widened in Q3 as SpectraCure advances clinical studies and seeks new funding.SPECQ3 2024
- Net loss widened in H1 2024 as SpectraCure advanced Q-PRO® clinical studies and market plans.SPECQ2 2024
- Q1 2025 saw continued losses and a planned rights issue as SpectraCure advances clinical studies.SPECQ1 2025
- Net loss widened as SpectraCure advanced clinical trials, with new funding needed by mid-2025.SPECQ4 2024
Next SpectraCure earnings date
Q3 202613 Nov, 2026
SpectraCure
Next SpectraCure earnings date
Q3 202613 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage